Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Wilms Tumor × Immunomodulating Agents × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Genitourinary 1

Conditions

Wilms Tumor 1 Multiple Myeloma 1 Hematologic Neoplasms 1

Interventions

Vincristine 2 sargramostim 1 regorafenib 1 racotumomab 1 pembrolizumab 1 entrectinib 1 Proteasome Inhibitors 1 Nivolumab 1 Monatide (IMS 3015) 1 Lenalidomide 1 Irinotecan 1 Immunomodulating Agents 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 CLR1404 1 Bortezomib 1 Biological Factors 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed

20 enrolled 9 charts

GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡